Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VSA012 injection in paroxysmal nocturnal hemoglobinuria
2026-526187-21-00Phase 2Authorised
- Sponsor
- BiSiRNA Therapeutics
- Start
- Oct 2026
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 5
01
Overview
Phase 2 trial of VSA012 in paroxysmal nocturnal hemoglobinuria (PNH) (7 arms), sponsored by BiSiRNA Therapeutics. Primary endpoints: Safety and tolerability, Lactate dehydrogenase change and 8 more. Planned start Oct 2026; status: authorised.
02
Drugs
VSA012
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2026-526187-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526187-21-00.